Bernard Bgaud

List of Publications by Year in Descending Order

109 papers	**5,061** citations
36 h-index	**68** g-index
116 ext. papers	**5,843** ext. citations
4.9 avg, IF	**5.23** L-index

#	Paper	IF	Citations
109	Assessing Causality from Case Reports **2021**, 246-256		
108	Overview of French databases available for studying anticancer drugs in real-life setting. *Fundamental and Clinical Pharmacology*, **2021**, 35, 76-85	3.1	3
107	Patterns of Benzodiazepine Use and Excess Risk of All-Cause Mortality in the Elderly: A Nationwide Cohort Study. *Drug Safety*, **2021**, 44, 53-62	5.1	6
106	Anticholinergic Activity of Psychotropic Drugs and Cognitive Impairment Among Participants Aged 45 and Over: The CONSTANCES Study. *Drug Safety*, **2021**, 44, 565-579	5.1	1
105	Hepatitis B vaccination and central demyelination - History, description and observed/expected analyses of 624 cases reported to the French pharmacovigilance over a 20-year period. *Vaccine*, **2019**, 37, 2142-2148	4.1	3
104	Assessing Causation from Case Reports **2019**, 723-745		1
103	A history of pharmacoepidemiology. *Therapie*, **2019**, 74, 175-179	3.8	2
102	Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis. *Vaccine*, **2018**, 36, 1548-1555	4.1	21
101	Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: A Disproportionality Analysis within the VAERS Database. *Drug Safety*, **2018**, 41, 767-774	5.1	2
100	An Automated System Combining Safety Signal Detection and Prioritization from Healthcare Databases: A Pilot Study. *Drug Safety*, **2018**, 41, 377-387	5.1	6
99	AuthorsꞌReply to Cohen et al.ꞌs Comment on "Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: A Disproportionality Analysis within the VAERS Database". *Drug Safety*, **2018**, 41, 1429-1430	5.1	
98	Methods for safety signal detection in healthcare databases: a literature review. *Expert Opinion on Drug Safety*, **2017**, 16, 721-732	4.1	31
97	Trends in incident use of benzodiazepines and Z-drugs in France from 2006 to 2012: a population-based study. *Pharmacoepidemiology and Drug Safety*, **2017**, 26, 162-169	2.6	23
96	An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders. *British Journal of Clinical Pharmacology*, **2017**, 83, 612-622	3.8	24
95	Comparison of two drug safety signals in a pharmacovigilance data mining framework. *Statistical Methods in Medical Research*, **2016**, 25, 615-29	2.3	3
94	Vaccine Case-Population: A New Method for Vaccine Safety Surveillance. *Drug Safety*, **2016**, 39, 1197-1209	5.1	1
93	Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase( ). *Drug Safety*, **2016**, 39, 689-96	5.1	23

92 Methods for the Post-Marketing Monitoring of Psychotropics Safety: Interests and Pitfalls **2016**, 27-44

91 A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases. *Drug Safety*, **2016**, 39, 251-60 — 5.1 — 21

90 The Benzodiazepine-Dementia Disorders Link: Current State of Knowledge. *CNS Drugs*, **2016**, 30, 1-7 — 6.7 — 89

89 Benzodiazepine, psychotropic medication, and dementia: A´population-based cohort study. *Alzheimer's and Dementia*, **2016**, 12, 604-13 — 1.2 — 57

88 Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users. *European Journal of Clinical Pharmacology*, **2016**, 72, 869-76 — 2.8 — 23

87 Causality assessment in pharmacovigilance: The French method and its successive updates. *Therapie*, **2016**, 71, 179-86 — 3.8 — 137

86 Imputabilité en pharmacovigilance´: de la méthode française originelle aux méthodes réactualisées. *Therapie*, **2016**, 71, 171-178 — 3.8 — 10

85 Homeopathic medical practice for anxiety and depression in primary care: the EPI3 cohort study. *BMC Complementary and Alternative Medicine*, **2016**, 16, 125 — 4.7 — 15

84 Compliance of psychotropic drug prescription with clinical practice guidelines in older inpatients. *Fundamental and Clinical Pharmacology*, **2016**, 30, 82-92 — 3.1 — 10

83 Utilization of psychotropic drugs by patients consulting for sleeping disorders in homeopathic and conventional primary care settings: the EPI3 cohort study. *Homeopathy*, **2015**, 104, 170-5 — 1.4 — 4

82 Is there really a link between benzodiazepine use and the risk of dementia?. *Expert Opinion on Drug Safety*, **2015**, 14, 733-47 — 4.1 — 64

81 Effects of Cydonia oblonga Miller leaf and fruit flavonoids on blood lipids and anti-oxydant potential in hyperlipidemia rats. *Journal of Ethnopharmacology*, **2015**, 169, 239-43 — 5 — 29

80 Benzodiazepine use and risk of Alzheimer's disease: case-control study. *BMJ, The*, **2014**, 349, g5205 — 5.9 — 313

79 Characteristics of patients consulting their regular primary care physician according to their prescribing preferences for homeopathy and complementary medicine. *Homeopathy*, **2014**, 103, 51-7 — 1.4 — 17

78 Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases. *Pharmacoepidemiology and Drug Safety*, **2014**, 23, 186-94 — 2.6 — 7

77 Effects of Cydonia oblonga Miller extracts on blood hemostasis, coagulation and fibrinolysis in mice, and experimental thrombosis in rats. *Journal of Ethnopharmacology*, **2014**, 154, 163-9 — 5 — 23

76 Management of upper respiratory tract infections by different medical practices, including homeopathy, and consumption of antibiotics in primary care: the EPI3 cohort study in France 2007-2008. *PLoS ONE*, **2014**, 9, e89990 — 3.7 — 46

75 Evaluation of post-marketing safety using spontaneous reporting databases **2014**, 332-344 — 0

74	Quantitative Signal Detection and Analysis in Pharmacovigilance **2014**, 331-354		10
73	Comparison of three methods (an updated logistic probabilistic method, the Naranjo and Liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference. *Drug Safety*, **2013**, 36, 1033-44	5.1	26
72	A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France. *Drug Safety*, **2013**, 36, 565-72	5.1	29
71	Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France. *Pharmacoepidemiology and Drug Safety*, **2013**, 22, 160-7	2.6	23
70	Relative risks from case-population data. *Epidemiology*, **2013**, 24, 935-6	3.1	6
69	Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. *Drug Safety*, **2012**, 35, 855-64	5.1	53
68	Benzodiazepine use and risk of dementia: prospective population based study. *BMJ, The*, **2012**, 345, e6231	39.9	246
67	Immunomodulatory and antitumour effects of abnormal Savda Munziq on S180 tumour-bearing mice. *BMC Complementary and Alternative Medicine*, **2012**, 12, 157	4.7	20
66	Early detection of pharmacovigilance signals with automated methods based on false discovery rates: a comparative study. *Drug Safety*, **2012**, 35, 495-506	5.1	19
65	An updated method improved the assessment of adverse drug reaction in routine pharmacovigilance. *Journal of Clinical Epidemiology*, **2012**, 65, 1069-77	5.7	21
64	Use of health insurance claim patterns to identify patients using nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. *Pharmacoepidemiology and Drug Safety*, **2012**, 21, 573-83	2.6	15
63	Who seeks primary care for sleep, anxiety and depressive disorders from physicians prescribing homeopathic and other complementary medicine? Results from the EPI3 population survey. *BMJ Open*, **2012**, 2,	3	14
62	Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system. *Drug Safety*, **2011**, 34, 577-85	5.1	10
61	The case-population study design: an analysis of its application in pharmacovigilance. *Drug Safety*, **2011**, 34, 861-8	5.1	26
60	Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study. *BMC Cardiovascular Disorders*, **2011**, 11, 46	2.3	36
59	Benchmarking the burden of 100 diseases: results of a nationwide representative survey within general practices. *BMJ Open*, **2011**, 1, e000215	3	14
58	Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. *British Journal of Clinical Pharmacology*, **2010**, 69, 295-302	3.8	22
57	Comparison of three methods (consensual expert judgement, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions: an assessment using reports made to a French pharmacovigilance centre. *Drug Safety*, **2010**, 33, 1045-54	5.1	38

#	Reference		
56	Medicine or ecstasy? The importance of the logo. *Fundamental and Clinical Pharmacology*, **2010**, 24, 233-7.	3.1	2
55	How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database. *European Journal of Clinical Pharmacology*, **2010**, 66, 743-8	2.8	27
54	Pharmacoepidemiological research using French reimbursement databases: yes we can!. *Pharmacoepidemiology and Drug Safety*, **2010**, 19, 256-65	2.6	96
53	Pharmacoepidemiology of psychotropic drugs: examples of current research challenges on major public health issues. *Epidemiologia E Psichiatria Sociale*, **2009**, 18, 107-113		6
52	Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting. *Statistics in Medicine*, **2009**, 28, 1774-92	2.3	37
51	The CADEUS study: burden of nonsteroidal anti-inflammatory drug (NSAID) utilization for musculoskeletal disorders in blue collar workers. *British Journal of Clinical Pharmacology*, **2009**, 67, 118-24	3.8	16
50	Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA. *Drug Safety*, **2009**, 32, 441-7	5.1	20
49	The risk of cognitive impairment in older community-dwelling women after benzodiazepine use. *Age and Ageing*, **2009**, 38, 226-8	3	31
48	A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding. *British Journal of Clinical Pharmacology*, **2008**, 66, 142-5	3.8	20
47	Impact of prescriber nonresponse on patient representativeness. *Epidemiology*, **2008**, 19, 186-90	3.1	17
46	Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. *British Journal of Clinical Pharmacology*, **2007**, 64, 482-8	3.8	52
45	Life-threatening adverse drug reactions at admission to medical intensive care: a prospective study in a teaching hospital. *Intensive Care Medicine*, **2007**, 33, 2150-7	14.5	24
44	Psychotropic drugs use and risk of heat-related hospitalisation. *European Psychiatry*, **2007**, 22, 335-8	6	90
43	Consumo de psicotrópicos y riesgo de hospitalización relacionado con el calor. *European Psychiatry (Ed Española)*, **2007**, 14, 408-412		
42	A new method for assessing drug causation provided agreement with experts' judgment. *Journal of Clinical Epidemiology*, **2006**, 59, 308-14	5.7	40
41	Effects of armagnac or vodka on platelet aggregation in healthy volunteers: a randomized controlled clinical trial. *Thrombosis Research*, **2005**, 115, 31-7	8.2	16
40	Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. *Drug Safety*, **2005**, 28, 35-51	5.1	64
39	Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001). *Drug Safety*, **2005**, 28, 731-40	5.1	77

#	Reference		
38	Impact of visits from pharmaceutical company representatives on antipsychotic prescription in primary care. *Schizophrenia Research*, **2005**, 77, 107-9	3.6	5
37	Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. *Psychological Medicine*, **2005**, 35, 307-15	6.9	82
36	Cytotoxicity of abnormal Savda Munziq aqueous extract in human hepatoma (HepG2) cells. *Fundamental and Clinical Pharmacology*, **2005**, 19, 465-72	3.1	27
35	Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance. *IEEE Transactions on Information Technology in Biomedicine*, **2005**, 9, 518-27		56
34	Agreement of expert judgment in causality assessment of adverse drug reactions. *European Journal of Clinical Pharmacology*, **2005**, 61, 169-73	2.8	70
33	The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions. *Pharmacoepidemiology and Drug Safety*, **2005**, 14, 285-6	2.6	35
32	Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. *Fundamental and Clinical Pharmacology*, **2004**, 18, 559-63	3.1	22
31	Patterns and correlates of benzodiazepine use in the French general population. *European Journal of Clinical Pharmacology*, **2004**, 60, 523-9	2.8	114
30	Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database. *Pharmacoepidemiology and Drug Safety*, **2004**, 13, 473-81	2.6	52
29	Differences between clinical trials and postmarketing use. *British Journal of Clinical Pharmacology*, **2004**, 57, 86-92	3.8	99
28	NSAID use profiles derived from reimbursement data in France. *Therapie*, **2004**, 59, 541-6	3.8	15
27	Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. *Pharmacoepidemiology and Drug Safety*, **2003**, 12, 271-81	2.6	83
26	Benzodiazepine utilization patterns in Alzheimer's disease patients. *Pharmacoepidemiology and Drug Safety*, **2003**, 12, 511-5	2.6	9
25	Effect of age of Armagnac extract and duration of treatment on antithrombotic effects in a rat thrombosis model. *Thrombosis Research*, **2003**, 111, 185-9	8.2	19
24	Effects of armagnac extracts on human platelet function in vitro and on rat arteriovenous shunt thrombosis in vivo. *Thrombosis Research*, **2003**, 110, 135-40	8.2	29
23	Drug reimbursement: indicators of inappropriate resource allocation. *British Journal of Clinical Pharmacology*, **2002**, 54, 528-34	3.8	17
22	Does age increase the risk of adverse drug reactions?. *British Journal of Clinical Pharmacology*, **2002**, 54, 550-2	3.8	32
21	Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study. *Neuroepidemiology*, **2002**, 21, 180-6	5.4	66

No.	Reference	IF	Cit.
20	Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. *Schizophrenia Research*, **2002**, 57, 147-56	3.6	53
19	Benzodiazepine use and risk of dementia: a nested case-control study. *Journal of Clinical Epidemiology*, **2002**, 55, 314-8	5.7	99
18	Rates of spontaneous reporting of adverse drug reactions in France. *JAMA - Journal of the American Medical Association*, **2002**, 288, 1588	27.4	112
17	Benzodiazepines and hip fractures in elderly people: case-control study. *BMJ: British Medical Journal*, **2001**, 322, 704-8		79
16	Benzodiazepine use in an elderly community-dwelling population. Characteristics of users and factors associated with subsequent use. *European Journal of Clinical Pharmacology*, **2001**, 57, 419-25	2.8	107
15	Hepatitis B vaccine and first episodes of central nervous system demyelinating disorders: a comparison between reported and expected number of cases. *British Journal of Clinical Pharmacology*, **2001**, 51, 489-90	3.8	19
14	Incidence of serious adverse drug reactions in general practice: a prospective study. *Clinical Pharmacology and Therapeutics*, **2001**, 69, 458-62	6.1	38
13	Comparison of patient questionnaires, medical records, and plasma assays in assessing exposure to benzodiazepines in elderly subjects. *Clinical Pharmacology and Therapeutics*, **2001**, 69, 445-50	6.1	26
12	Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. *British Journal of Clinical Pharmacology*, **2000**, 49, 80-6	3.8	43
11	**2000**,		21
10	Is reporting rate a good predictor of risks associated with drugs?. *British Journal of Clinical Pharmacology*, **1999**, 47, 329-31	3.8	68
9	The role of pharmacoepidemiology in pharmacovigilance: a conference at the 6th ESOP Meeting, Budapest, 28 September 1998 **1999**, 8, S1-S7		
8	Abuse of prescription medicines in southwestern France. *Annals of Pharmacotherapy*, **1997**, 31, 847-50	2.9	24
7	Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. *British Journal of Clinical Pharmacology*, **1997**, 44, 513-8	3.8	96
6	Temporal trends in spontaneous reporting of unlabelled adverse drug reactions. *British Journal of Clinical Pharmacology*, **1997**, 44, 299-301	3.8	24
5	Comparing the toxicity of two drugs in the framework of spontaneous reporting: a confidence interval approach. *Journal of Clinical Epidemiology*, **1996**, 49, 121-3	5.7	22
4	Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. *New England Journal of Medicine*, **1996**, 335, 609-16	59.2	962
3	Power and weakness of spontaneous reporting: a probabilistic approach. *Journal of Clinical Epidemiology*, **1992**, 45, 283-6	5.7	53

2   Random models for margins of a 2 x 2 contingency table and application to pharmacovigilance. *Statistics in Medicine*, **1991**, 10, 991-9

2.3   7

1   Statistical Methods of Evaluating Pharmacovigilance Data257-264

2   Random models for margins of a 2 x 2 contingency table and application to pharmacovigilance. *Statistics in Medicine*, **1991**, 10, 991-9

2.3   7